The ZIRCON Trial

EP: 1.The Evolvement of Imaging in ccRCC

EP: 2.The Biggest Challenges in Distinguishing ccRCC From Benign Renal Masses

EP: 3.Strengths and Weaknesses of Imaging Modalities in ccRCC

EP: 4.Treatment or Lack of Treatment of Small Renal Masses

EP: 5.Decision-Making in Small Renal Masses

EP: 6.Current Unmet Needs in ccRCC Diagnosis

EP: 7.Early Detection of ccRCC

EP: 8.Key Benefits of PET in ccRCC Risk Stratification

Now Viewing

EP: 9.The ZIRCON Trial

EP: 10.The MOA of TLX250

EP: 11.Top-Line Results of the Phase 3 ZIRCON Study

EP: 12.Risk Stratification in ccRCC: The Impact in Patient Populations

EP: 13.Lymph Node–Positive Kidney Disease: Future Implications of PET Imaging

EP: 14.Overcoming Challenges for Wider Adoption of TLX250

EP: 15.The Future of PET Imaging Agents

EP: 16.The Logistical Challenges in ccRCC Treatment

The ZIRCON Trial and Molecular Imaging

Main Discussion Topics:

• The ZIRCON trial evaluated a novel PET tracer (89Zr-TLX250) for characterizing small renal masses.
• The trial demonstrated high sensitivity and specificity for identifying clear cell renal cell carcinoma (ccRCC).
• Positive predictive value exceeded 90% for ccRCC.
• Negative predictive value was less impressive, with 30% still having ccRCC when test negative.

Key Points for Physicians:

• 89Zr-TLX250 PET showed greater than 85% accuracy for identifying ccRCC.
• Positive predictive value of greater than 90% indicates high reliability when positive.
• Negative predictive value was approximately 70%.
• Represents entry into the “molecular era” of kidney cancer imaging

Notable Insights:

The high positive predictive value makes this a potentially valuable test when positive, though negative tests require careful interpretation.

Clinical Significance:

This molecular imaging approach represents a significant advance in noninvasive characterization of renal masses and may reduce unnecessary interventions.